Brief: Inhibikase Therapeutics Reports Full Year 2021 Financial Results
31/03/2022 22:02
March 31 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS REPORTS FULL YEAR 2021 FINANCIAL
RESULTS
AND HIGHLIGHTS RECENT PERIOD ACTIVITY
* INHIBIKASE THERAPEUTICS - EXPECTS EXISTING CASH AND CASH
EQUIVALENTS SUFFICIENT TO FUND EXPENDITURE REQUIREMENTS INTO Q3
OF 2023
Source text for Eikon: ID:nPnbj61yna
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary